JP2017507959A - 選択された抗コリン作動性両性イオンの使用 - Google Patents

選択された抗コリン作動性両性イオンの使用 Download PDF

Info

Publication number
JP2017507959A
JP2017507959A JP2016556253A JP2016556253A JP2017507959A JP 2017507959 A JP2017507959 A JP 2017507959A JP 2016556253 A JP2016556253 A JP 2016556253A JP 2016556253 A JP2016556253 A JP 2016556253A JP 2017507959 A JP2017507959 A JP 2017507959A
Authority
JP
Japan
Prior art keywords
compound
hydroxyacetoxy
cyclopentyl
carboxymethyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016556253A
Other languages
English (en)
Japanese (ja)
Inventor
ニコラス エス. ボドール,
ニコラス エス. ボドール,
Original Assignee
ボドール ラボラトリーズ, インコーポレイテッド
ボドール ラボラトリーズ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ボドール ラボラトリーズ, インコーポレイテッド, ボドール ラボラトリーズ, インコーポレイテッド filed Critical ボドール ラボラトリーズ, インコーポレイテッド
Publication of JP2017507959A publication Critical patent/JP2017507959A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2016556253A 2014-03-13 2015-03-12 選択された抗コリン作動性両性イオンの使用 Withdrawn JP2017507959A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461952342P 2014-03-13 2014-03-13
US61/952,342 2014-03-13
PCT/US2015/020137 WO2015138700A1 (en) 2014-03-13 2015-03-12 Use of selected anticholinergic zwitterions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020050858A Division JP6732356B2 (ja) 2014-03-13 2020-03-23 選択された抗コリン作動性両性イオンの使用

Publications (1)

Publication Number Publication Date
JP2017507959A true JP2017507959A (ja) 2017-03-23

Family

ID=54072392

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016556253A Withdrawn JP2017507959A (ja) 2014-03-13 2015-03-12 選択された抗コリン作動性両性イオンの使用
JP2018511381A Active JP6750900B2 (ja) 2014-03-13 2016-08-26 選択された抗コリン作用性双性イオンの使用
JP2020050858A Active JP6732356B2 (ja) 2014-03-13 2020-03-23 選択された抗コリン作動性両性イオンの使用
JP2020115416A Active JP6968457B2 (ja) 2014-03-13 2020-07-03 選択された抗コリン作動性両性イオンの使用
JP2020134413A Active JP6981694B2 (ja) 2014-03-13 2020-08-07 選択された抗コリン作用性双性イオンの使用

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018511381A Active JP6750900B2 (ja) 2014-03-13 2016-08-26 選択された抗コリン作用性双性イオンの使用
JP2020050858A Active JP6732356B2 (ja) 2014-03-13 2020-03-23 選択された抗コリン作動性両性イオンの使用
JP2020115416A Active JP6968457B2 (ja) 2014-03-13 2020-07-03 選択された抗コリン作動性両性イオンの使用
JP2020134413A Active JP6981694B2 (ja) 2014-03-13 2020-08-07 選択された抗コリン作用性双性イオンの使用

Country Status (3)

Country Link
US (2) US10632067B2 (enExample)
JP (5) JP2017507959A (enExample)
WO (2) WO2015138700A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150259283A1 (en) 2014-03-13 2015-09-17 Brickell Biotech, Inc. Formulation for soft anticholinergic analogs
JP2017507959A (ja) 2014-03-13 2017-03-23 ボドール ラボラトリーズ, インコーポレイテッド 選択された抗コリン作動性両性イオンの使用
KR20250024093A (ko) 2015-07-21 2025-02-18 보도르 라보래토리즈, 인크. 연성 항콜린제 유사체를 위한 제제
JP2019519572A (ja) * 2016-07-01 2019-07-11 ボドール ラボラトリーズ, インコーポレイテッド Copdを処置するための組成物および方法
TWI767507B (zh) 2016-07-21 2022-06-11 美商波德實驗股份有限公司 軟性抗膽鹼類似物之製劑
EP4164606A4 (en) * 2020-06-11 2024-07-03 The Trustees Of Columbia University In The City Of New York Methods and compositions for preventing and treating myopia with trichostatin a, a histone deacetylase (hdac) inhibitor, and derivatives thereof
CN116133665A (zh) * 2020-06-11 2023-05-16 纽约市哥伦比亚大学理事会 用于用鞘氨醇-1-磷酸受体调节剂芬戈莫德及其衍生物预防和治疗近视的方法和组合物
JP2023530679A (ja) * 2020-06-11 2023-07-19 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク フェノテロール臭化水素酸塩、β2アドレナリン受容体アゴニスト、及びその誘導体を用いて近視を予防及び治療するための方法及び組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007308398A (ja) * 2006-05-17 2007-11-29 Chang Gung Memorial Hospital 目薬、及びその製造方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0786997A4 (en) * 1994-10-27 1998-03-11 Merck & Co Inc MUSCARINE ANTAGONISTS
US6433003B1 (en) 1999-04-23 2002-08-13 Arthur M. Bobrove Method for treating hyperhidrosis in mammals
WO2003026585A2 (en) 2001-09-26 2003-04-03 Lukacsko Alison B Compositions and methods for inhibiting eccrine perspiration in humans
US7399861B2 (en) * 2005-11-10 2008-07-15 Bodor Nicholas S Soft anticholinergic esters
WO2007058971A2 (en) 2005-11-10 2007-05-24 Bodor Nicholas S Soft anticholinergic esters
RU2009128703A (ru) * 2006-12-26 2011-02-10 Клт Плаг Диливери, Инк. (Us) Имплантаты, доставляющие лекарства, для уменьшения оптических дефектов
MX2010004262A (es) 2007-10-18 2010-05-14 Stiefel Res Australia Pty Ltd Formulaciones topicas de glicopirrolato.
CN105050596A (zh) 2013-03-15 2015-11-11 博多尔实验仪器公司 用于治疗多汗症的抗胆碱能格隆溴铵酯
JP2017507959A (ja) * 2014-03-13 2017-03-23 ボドール ラボラトリーズ, インコーポレイテッド 選択された抗コリン作動性両性イオンの使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007308398A (ja) * 2006-05-17 2007-11-29 Chang Gung Memorial Hospital 目薬、及びその製造方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PHARMAZIE,2008, VOL.63, NO.3, PP.200-209, JPN6018049103, ISSN: 0003938759 *

Also Published As

Publication number Publication date
JP2020105218A (ja) 2020-07-09
WO2015138700A1 (en) 2015-09-17
WO2017040307A1 (en) 2017-03-09
JP6968457B2 (ja) 2021-11-17
JP2020158545A (ja) 2020-10-01
JP2018529666A (ja) 2018-10-11
US20180243209A1 (en) 2018-08-30
JP6750900B2 (ja) 2020-09-02
JP6981694B2 (ja) 2021-12-17
JP6732356B2 (ja) 2020-07-29
US20150374621A1 (en) 2015-12-31
US10632067B2 (en) 2020-04-28
US10335367B2 (en) 2019-07-02
JP2020176154A (ja) 2020-10-29

Similar Documents

Publication Publication Date Title
JP6732356B2 (ja) 選択された抗コリン作動性両性イオンの使用
EP3681500B1 (en) Use of pilocarpine hydrochloride for the treatment of presbyopia
CN101495117B (zh) 含酰胺化合物的水性液体制剂
JP7174175B2 (ja) 近視の治療、近視の予防および/または近視の進行抑制のための医薬
JP7625713B2 (ja) 視力障害性眼疾患の治療または予防におけるペネヒクリジンの使用
CN115776894A (zh) T型钙通道调节剂的使用方法
EP3416617B1 (en) Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human
WO2023202705A1 (zh) 一种眼用制剂及其在治疗老花眼中的应用
JP2021501803A5 (enExample)
EP3616723B1 (en) Use of nicotinic acid or prazosin for treating myopia
Kubaisi et al. Ocular allergy: an updated review
TWI654976B (zh) 選定的抗膽素激導性兩性離子之用途
KR20240050324A (ko) 빈포세틴을 사용한 근시치료방법
JP2020514347A (ja) チオトロピウムを有効成分として含有する近視予防、近視治療および/または近視進行抑制剤
JP2023043810A (ja) アレルギー性結膜炎治療剤
Guan et al. Potential Application of Bendazac L-Lysine for Controlling Myopia Progression, as Demonstrated in Two Experimental Guinea Pig Myopia Models
HK40081663A (en) Use of pilocarpine hydrochloride for the treatment of ocular conditions
CN112243375A (zh) 选择性syk抑制剂的使用方法及药物组合物
TW202237075A (zh) 抑制小兒近視進展用點眼劑及小兒近視進展抑制劑之篩選方法
HK40034331B (en) Use of pilocarpine hydrochloride for the treatment of presbyopia
HK40034331A (en) Use of pilocarpine hydrochloride for the treatment of presbyopia
EA041892B1 (ru) Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180308

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190612

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200323

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200420

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20200423